TRUDY: Comparison Between Two Methods of Pancreatic Transection in Distal Pancreatectomy

Sponsor
Azienda Ospedaliera Universitaria Integrata Verona (Other)
Overall Status
Unknown status
CT.gov ID
NCT03880773
Collaborator
(none)
152
1
2
30
5.1

Study Details

Study Description

Brief Summary

Several systematic reviews have investigated the management of the pancreatic stump in order to reduce the postoperative pancreatic fistula (POPF) rate after distal pancreatectomy (DP). The appropriate closure technique of the pancreatic stump is still debated. There is no published experience about the comparison of the Endo GIA Reinforced Reload with Tri-Staple Technology (TS) versus Harmonic Focus (US) after distal pancreatectomy (DP) regarding the reduction of POPF.

The investigators want to compare the incidence of clinically-relevant POPF (CR-POPF) after DP, depending upon the transection technique (TS versus US).

This is a randomized controlled, multicenter, patient-blinded, superiority trial. This protocol was designed according to the SPIRIT guidelines.

Two groups of 76 patients (152 in total) with an indication for elective minimally invasive or open DP for a lesion of the body-tail of the pancreas. The two techniques analyzed are Endo GIA Reinforced Reload with Tri-Staple Technology (TS) and Harmonic Focus (US) as control.

The primary endpoint is to evaluate the incidence of CR-POPF rate after DP. Secondary endpoints are intraoperative outcomes (blood loss, operative time and conversion of the minimally invasive procedure), postoperative outcomes (complications rate; hospitalization parameters to 90 days; mortality) and treatment costs.

Condition or Disease Intervention/Treatment Phase
  • Device: Stapler
  • Device: ultrasonic shears
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
152 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Participant)
Primary Purpose:
Treatment
Official Title:
Tri Stapler vs. Ultrasonic Scalpel in Distal Pancreatectomy
Actual Study Start Date :
Jul 1, 2018
Anticipated Primary Completion Date :
Dec 31, 2020
Anticipated Study Completion Date :
Dec 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Experimental: Stapler

Device: Stapler
for transection of the pancreas and pancreatic stump treatment

Active Comparator: ultrasonic shears

Device: ultrasonic shears
for transection of the pancreas and pancreatic stump treatment

Outcome Measures

Primary Outcome Measures

  1. Rate of Pancreatic fistula [90 days]

    pancreatic fistula according to International Study Group of Pancreatic Surgery (ISGPS) 2017 definition

Secondary Outcome Measures

  1. Operative time [intra-operatively]

  2. Rate of postoperative overall and specific complications [30 days, 90 days]

    abdominal collections, delayed gastric emptying, hemorrhage, sepsis, wound infections

  3. Rate of re-operations or percutaneous drainage [30 days, 90 days]

    re-operations rate or percutaneous drainage rate

  4. Cost-analysis [90 days]

    intra and post-operative costs

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Scheduled for elective DP via a minimally invasive (laparoscopic or robotic) or open technique, either preserving the spleen or with splenectomy, depending on the diagnosis/nature of the tumor

  • ASA score < 4

  • Ability of the subject to understand character and individual consequences of the clinical trial

  • Written informed consent

Exclusion Criteria:
  • Pancreas thickness >17mm measured at the intraoperative ultrasound at the pancreatic transection level

  • Metastatic disease

  • Kidney or adrenal gland resection

  • Arterial resection (celiac axis, superior mesenteric artery, hepatic artery)

  • Intestinal resections and anastomoses or stoma

  • Acute necrotizing and chronic pancreatitis

  • Immune suppressed patients

  • Pregnant women

  • Patients with contraindications for distal pancreatectomy

  • Impaired mental state or language problems

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ospedale Policlinico GB Rossi Verona Italy 37134

Sponsors and Collaborators

  • Azienda Ospedaliera Universitaria Integrata Verona

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Azienda Ospedaliera Universitaria Integrata Verona
ClinicalTrials.gov Identifier:
NCT03880773
Other Study ID Numbers:
  • TRUDY
First Posted:
Mar 19, 2019
Last Update Posted:
Mar 19, 2019
Last Verified:
Jan 1, 2019
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 19, 2019